Argenx SE

Argenx shares rise on strong oncology data and a diversified bispecific pipeline, highlighting AMG 557’s melanoma success and future regulatory prospects.

Argenx SE, a European biotechnology firm, has reported a 95.3% year-over-year increase in revenue, driven by strong sales of its flagship antibody therapy, VYVGART, which has shown promising efficacy in treating seropositive generalized myasthenia g…

Argenx SE, a Berlin-based biotechnology firm, has achieved remarkable growth and a market capitalization of over €41 billion, driven by its focus on antibody-based therapies for autoimmune and oncology indications, but faces regulatory, competitiv…

Argenx SE, a European biotechnology firm, has seen a significant increase in its stock value following the release of positive clinical data for its antibody-based therapeutic pipeline, with investors anticipating successful late-stage trials and po…

Argenx SE has demonstrated remarkable growth and financial performance, driven by its focus on antibody-based therapies for severe autoimmune diseases and oncology, and its ability to navigate complex reimbursement environments and operational chall…

Argenx SE, a European biopharmaceutical firm, has experienced a short-term decline in its share price, but its inclusion in the Euro Stoxx 50 index and strong positioning in the autoimmune and oncology markets reinforce its long-term value propositi…

Argenx, a biotechnology company, will present at upcoming investor conferences, with its stock price fluctuating over the past year and current valuation metrics including a price-to-earnings ratio of 36.59.

Argenx SE’s stock price has surged 31% in the past month, driven by the company’s strong quarterly performance, despite regulatory warnings and a securities investigation.

Argenx SE, a biotech company, partners with tennis legend Monica Seles to raise awareness for myasthenia gravis and support patients with rare diseases.

Argenx SE’s stock price surges following analyst upgrades from Barclays, JPMorgan, and Deutsche Bank, with price targets raised to $220, $200, and $250 respectively.